13
|
von Elverfeldt D, Maier A, Duerschmied D, Braig M, Witsch T, Wang X, Mauler M, Neudorfer I, Menza M, Idzko M, Zirlik A, Heidt T, Bronsert P, Bode C, Peter K, von Zur Muhlen C. Dual-contrast molecular imaging allows noninvasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging. Circulation 2014; 130:676-87. [PMID: 24951772 DOI: 10.1161/circulationaha.113.008157] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Inflammation and myocardial necrosis play important roles in ischemia/reperfusion injury after coronary artery occlusion and recanalization. The detection of inflammatory activity and the extent of myocardial necrosis itself are of great clinical and prognostic interest. We developed a dual, noninvasive imaging approach using molecular magnetic resonance imaging in an in vivo mouse model of myocardial ischemia and reperfusion. METHODS AND RESULTS Ischemia/reperfusion injury was induced in 10-week-old C57BL/6N mice by temporary ligation of the left anterior descending coronary artery. Activated platelets were targeted with a contrast agent consisting of microparticles of iron oxide (MPIOs) conjugated to a single-chain antibody directed against a ligand-induced binding site (LIBS) on activated glycoprotein IIb/IIIa (LIBS-MPIOs). After injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardial necrosis; these imaging experiments were also performed in P2Y12 (-/-) mice. All imaging results were correlated to immunohistochemistry findings. Activated platelets were detectable by magnetic resonance imaging via a significant signal effect caused by LIBS-MPIOs in the area of left anterior descending coronary artery occlusion 2 hours after reperfusion. In parallel, late gadolinium enhancement identified the extent of myocardial necrosis. Immunohistochemistry confirmed that LIBS-MPIOs bound significantly to microthrombi in reperfused myocardium. Only background binding was found in P2Y12 (-/-) mice. CONCLUSIONS Dual molecular imaging of myocardial ischemia/reperfusion injury allows characterization of platelet-driven inflammation by LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement. This noninvasive imaging strategy is of clinical interest for both diagnostic and prognostic purposes and highlights the potential of molecular magnetic resonance imaging for characterizing ischemia/reperfusion injury.
Collapse
Affiliation(s)
- Dominik von Elverfeldt
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Alexander Maier
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Daniel Duerschmied
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Moritz Braig
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Thilo Witsch
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Xiaowei Wang
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Maximilian Mauler
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Irene Neudorfer
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Marius Menza
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Marco Idzko
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Andreas Zirlik
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Timo Heidt
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Peter Bronsert
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Christoph Bode
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Karlheinz Peter
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.)
| | - Constantin von Zur Muhlen
- From the Department of Radiology-Medical Physics (D.v.E., M.B., M. Menza), Department of Pneumology (M.I.), and Institute of Pathology and Comprehensive Cancer Center (P.B.), University Medical Center Freiburg, Freiburg, Germany; Department of Cardiology I, University Heart Center Freiburg, Freiburg, Germany (A.M., D.D., T.W., M. Mauler, I.N., A.Z., T.H., C.B., C.v.z.M.); Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia (X.W., K.P.); Faculty of Biology, University Freiburg, Freiburg, Germany (M. Mauler); and Center for Systems Biology, Massachusetts General Hospital, Boston (T.H.).
| |
Collapse
|
14
|
Ardipradja K, Yeoh SD, Alt K, O'Keefe G, Rigopoulos A, Howells DW, Scott AM, Peter K, Ackerman U, Hagemeyer CE. Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies. Nucl Med Biol 2013; 41:229-37. [PMID: 24440583 DOI: 10.1016/j.nucmedbio.2013.12.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Revised: 11/14/2013] [Accepted: 12/07/2013] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Activated platelets are key players in thrombosis and inflammation. We previously generated single-chain antibodies (scFv) against ligand-induced binding sites (LIBS) on the highly abundant platelet glycoprotein integrin receptor IIb/IIIa. The aim of this study was the construction and characterisation of a novel (18)F PET radiotracer based on this antibody. METHODS ScFv(anti-LIBS) and control antibody mut-scFv were reacted with N-succinimidyl-4-[(18)F]fluorobenzoate (S[(18)F]FB). Radiolabeled scFv was incubated with in vitro formed platelet clots and injected into mice with FeCl(3) induced thrombus in the left carotid artery. Clots were imaged in the PET scanner and amount of radioactivity measured using an ionization chamber and image analysis. Assessment of vessel injury as well as the biodistribution of the radiolabeled scFv was studied. RESULTS After incubation with increasing concentrations of (18)F-scFv(anti-LIBS) clots had retained significantly higher amounts of radioactivity compared to clots incubated with radiolabeled (18)F-mut-scFv (13.3 ± 3.8 vs. 3.6 ± 1 KBq, p < 0.05, n = 9, decay corrected). In the in vivo experiments we found an high uptake of the tracer in the injured vessel compared with the non-injured vessel, with 12.6 ± 4.7% injected dose per gram (ID/g) uptake in the injured vessel and 3.7 ± 0.9% ID/g in the non-injured vessel 5 minutes after injection (p < 0.05, n = 6). CONCLUSIONS Our results show that the novel antibody radiotracer (18)F-scFv(anti-LIBS) is useful for the sensitive detection of activated platelets and thrombosis. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE We describe the first (18)F variant of a scFv(anti-LIBS) against activated platelets. This diagnostic agent could provide a powerful tool for the assessment of acute thrombosis and inflammation in patients in the future.
Collapse
Affiliation(s)
- Katie Ardipradja
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia; Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
| | - Shinn Dee Yeoh
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
| | - Karen Alt
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia
| | - Graeme O'Keefe
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia
| | - Angela Rigopoulos
- Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - David W Howells
- The Florey Institute of Neuroscience and Mental Health, Austin Hospital, Melbourne, Australia
| | - Andrew M Scott
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - Karlheinz Peter
- Atherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia
| | - Uwe Ackerman
- Departments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australia; Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia; Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Australia
| | - Christoph E Hagemeyer
- Vascular Biotechnology Laboratory, Baker IDI, Melbourne, Australia; Central Clinical School, Monash University, Melbourne, Australia.
| |
Collapse
|